Novacyt S.A. Acquisition update (6954J)
17 Agosto 2023 - 11:16AM
UK Regulatory
TIDMNCYT
RNS Number : 6954J
Novacyt S.A.
17 August 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Acquisition update
Paris, France and Eastleigh, UK - 17 August 2023 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, notes today's announcement by Yourgene Health
plc ("Yourgene"), in relation to the recommended cash offer made by
Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned
subsidiary of Novacyt, for the entire issued and to be issued share
capital of Yourgene announced on 3 July 2023 (the "Acquisition"),
which is to be effected by means of a Court-sanctioned scheme of
arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
A circular in relation to the Scheme was published by Yourgene on
27 July 2023 (the "Scheme Document").
Capitalised terms used in this announcement shall, unless
otherwise defined, have the same meaning as set out in the Scheme
Document.
At the Court Meeting and the General Meeting held earlier today,
convened in accordance with an order of the Court dated 26 July
2023, all resolutions to approve and implement the Scheme were
passed by the requisite majorities of Yourgene's shareholders.
Yourgene's full announcement can be found here:
polaris.brighterir.com/public/yourgenehealth/news/rns/story/
xp39emw
The Acquisition remains subject to the satisfaction or (where
applicable) waiver of the remaining Conditions and to the further
terms set out in Part III of the Scheme Document, including the
Court sanctioning the Scheme at the Court Sanction Hearing and the
delivery of a copy of the Court Order to the Registrar of
Companies. The expected timetable of principal events for the
implementation of the Scheme remains as set out in the Scheme
Document. The dates are indicative only and are subject to change.
The dates will depend, among other things, on the date upon which:
(i) the Conditions are satisfied or (if capable of waiver) waived;
(ii) the Court sanctions the Scheme; and (iii) a copy of the Court
Order is delivered to the Registrar of Companies.
Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
Numis (Financial Adviser and Joint Broker
to Novacyt and Financial Adviser to Novacyt
UK) +44 (0)20 7260 1000
Freddie Barnfield / Stuart Ord / Duncan
Monteith / Jack McLaren
SP Angel Corporate Finance LLP (Nominated
Adviser and Joint Broker to Novacyt) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
Novacyt is headquartered in Vélizy in France with offices in
Stokesley and Eastleigh, UK, and is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQPRMFTMTBBBAJ
(END) Dow Jones Newswires
August 17, 2023 12:16 ET (16:16 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De May 2023 a May 2024